Time for a Change: BIO Study--US Students Falling Behind in Bioscience Education
The Biotechnology Industry Organization (BIO) kicked off its annual meeting in Atlanta, Georgia today and shortly thereafter, issued a press release detailing an education study (that it commissioned) which suggests that American high school students are continuing to fall behind in life sciences education and competitiveness. The timing of the BIO education report is curious, given that over 100,000 life sciences employees have lost their jobs over the past several years and more job cuts at pharmaceutical and biotechnology companies are expected in the next six months or so.
The report concluded that “middle and high school students across the country are generally falling behind in life sciences, and the nation is at risk of producing a dearth of qualified workers for the life sciences industry. Students are showing less interest in taking life sciences and science courses, and high schools are doing a poor job of preparing students for college-level science, The deficiencies will hurt the country's competitiveness with the rest of the world in the knowledge-based economy.”
Some of the report's finding include:
- 52 percent of 12th graders are at or above a basic level of achievement in the sciences as measured by the NAEP science test
- Average scores on the NAEP for 12th graders in the sciences and life sciences declined from 1996 to 2005
- Only 28 percent of high school students taking the ACT reached a score indicating college readiness for biology.
The report also found a deficiency in the number of well-qualified biology teachers available in high school, with one-in-eight biology teachers not certified to teach biology. To improve U.S. competitiveness in the biosciences industry, the report recommends that states incorporate biotechnology into their science standards, make sure students are ready to take college biosciences courses and focus more on professional development for teachers.
While BIO ought to be commended for the study, the results and the conclusions of the report are nothing new and have been known for over a decade by industry thought leaders and life sciences industry executives. The crux of the problem is that neither academia nor industry is willing to provide funds or invests in ways to find a solution to this vexing, ongoing issue. Also,while high school science curriculum experts and teachers are typically cited as the cause of the problem, most of the blame more aptly lies with life science educators at the undergraduate and graduate school levels.
Today, many US high schools and community colleges already offer life sciences and biotechnology training to their students. In fact, biotechnology curriculum development and outreach has been ongoing in US for well over a decade. For example, Bio-Link, an NSF-funded consortium of community colleges that began in the late 1990s, has diligently worked to create a network of community colleges and high schools that offer biotechnology education and training ranging from biomanufacturing to bioinformatics to forensic DNA sciences. Further, a quick perusal of many high schools and science academies in biotechnology-rich locales like the Northeast, California, New Jersey, Maryland, North Carolina and others reveals that life sciences education and training are readily available to many students interested in biology and bioscience.
In my opinion, the system doesn't break down at the high school level but at the undergraduate and graduate school levels. This is because for the past 15 years, many undergraduate life sciences courses have jettisoned their hands on laboratory components in favor of more lecture driven and e-based learning experiences. This is because these laboratories are costly to run and extremely labor intensive. Further, many undergraduate students may choose not pursue science careers because of the mistaken perception that life sciences jobs require a PhD. Ironically, there are many more jobs in the life sciences industry for students with undergraduate or masters' degrees than for those with PhD. This is because there is a glut of PhDs in today's market and the number of jobs in academia and the life sciences industry are growing smaller. I believe that academia and industry are responsible for the rapidly declining job market for PhD-life sciences.
First, let's look at academia. Most academicians who are charged with training PhDs and postdoctoral fellows have little appreciation or understanding of the technical and regulatory skill sets required in the life sciences industry. Second, many academics don't feel that it is their responsibility to prepare students and postdoctoral fellows for jobs in industry because that is tantamount to job training—a big no-no in academic circles. Finally,and perhaps most important, graduate programs are reluctant to provide career counseling or job-specific training for their students because it might interfere with their productivity, which in turn may reduce the amount of data principal investigators have to write papers and win grants to fund their laboratories. In other words, there is little or no incentive for education and training to change at the graduate level because there is no benefit or upside to principal investigators and tenured faculty members.
While the American life sciences industry has loudly and repeatedly complained about a lack of qualified job candidates to work at its companies, they have done little to support and fund efforts to reform US life science education and training. This is likely because many life sciences executives contend that they are in business not education and the responsibility to prepare students for careers in science should not fall on them. Rather, it rightfully belongs in the purview of secondary and post secondary educational institutions. And, rather than train new employees without previous industrial experience (to inject new talent and ideas into their organizations), companies typically only hire job candidates with previous industrial experience. As many newly minted PhD and postdoctoral students frequently ask: “How are we suppose to get industrial experience if nobody will hire us without previous industrial experience?” Good question!
The BIO report warns that the US is falling behind in bioscience education and American life science companies may experience workforce shortages in the future. The fact that about 100,000 (many of whom were scientists) pharmaceutical employees have lost their jobs over the past several years, suggests otherwise. Nevertheless, American science education and training needs to be improved and reformed if the US wants to maintain its dominance in the life sciences. The piecemeal approach that has been pursued for past decade or so hasn't worked. And why should it? Neither academia nor industry, the two main players in the story, don't really have any “skin in the game.” In other words, they have nothing to lose right now!
I believe that its time for academia, industry and government to come together to craft a cohesive, national life science curriculum that meets the needs of all stakeholders. We have a President in the White House who believes in science, the ingenuity of the American people and change. The time is now!
Until next time...
Good Luck and Good Job Hunting!!!!!

As we all know, the H1NI pandemic has been raging on for close too 10 ten days now. Curiously, “Fear & The Flu: The New Age of Pandemics” is the title this week’s cover story in Newsweek magazine. From an informational standpoint point, “this may be too little, too late”—as the old saying goes. While the Internet has been around for over twenty years now, government agencies, most notably the US Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) continue to rely almost exclusively on old media to communicate with the American public during infectious disease outbreaks. Apparently, the administrators who run these government agencies haven’t been listening closely enough to President Obama’s assertion that “we live in the digital age.”
Over the past several years, I have publicly called for fundamental changes in graduate education and training for life scientists. To that end, I was delighted to read an OP-ED piece in today’s New York Times entitled “End Universities as We Know It” written by Professor Mark C. Taylor, Chairperson of the religion department at Columbia University.
Previously, the US Congress proposed legislation to create a regulatory approval process to allow the Food and Drug Administration (FDA) to approve generic versions of blockbuster biotechnology drugs known as follow-on biologics (FOBs). While a regulatory pathway exists for approval of generic versions of small molecule drugs (as outlined in the
That methicillin resistant Staphylococcus aureus (MRSA) is in the news again is not surprising. However, to my knowledge, Nicholas Kristof‘s article in today’s New York Times may be the first Op-Ed piece written by a non-scientist about the growing threat and seriousness of MRSA infections. Mr. Kristof apparently became aware of MRSA when he was contacted by Tom Anderson, MD, a Camden, Indiana physician who was experiencing “phenomenal levels of MRSA infections" in his community.
According to a report on NPR’s All Things Considered program, the Obama Administration has nominated Margaret Hamburg, MD to head the US Food and Drug Administration. Dr. Hamburg is a former health commissioner in New York City who has worked on issues surrounding infectious diseases and bioterrorism. In New York, she instituted a needle-exchange program to help prevent the spread of HIV. She also set up a program, in which health workers went to tuberculosis patients’ homes to help them manage their drug regimens.
This morning, while doing my usual Twitter review, I came across a tweet from the
For the past decade or so, I have worked as a career counselor at national scientific meetings where I present seminars about resume writing, interviewing techniques and other career related issues. About two years ago, I started to hear about the fierce competition for H-1 and J-1 visas that foreign students must obtain to remain in the US to continue their studies and research. Many of the foreign students that I talked with sounded more like immigration lawyers than graduate students or postdocs—I was amazed at how well informed they were about visa availability and the changes and loopholes in US immigration law that can be exploited to obtain visas.
An intrepid reader of BioJobBlog alerted me to a new venture started by Donna Roberts and Dawn Abrams. They allegedly run an operation called
For the past year or so, I have been dealing with
My oldest son is a high school sophomore and is currently taking “honors” biology. While he is generally an “A” student, it is obvious that he is neither interested in biology nor motivated to perform to his ability in the class. Many of his “A-student friends” are also not doing well in biology class. This gave me pause for concern as a life-long science educator (and certified high school biology teacher). With this as a backdrop, I decided to meet with his teacher to determine why so many good students are underperforming in her class. After meeting with his teacher on two separate occasions, it was readily apparent why so many talented students were performing poorly in her class—she lacks the requisite educational and scientific skills to be an effective biology teacher. This was confirmed by the head of curriculum development in my school district who told me that the last time that the district had an opening for a high school biology teacher he had two applicants (neither of which had strong biology credentials)—this in the state of New Jersey which is touted to have one of the best public school systems in America.
I believe in free enterprise and that publicly-traded companies ought to be able to buy one another if a deal makes sense. In any other financial market, Pfizer’s impending acquisition of Wyeth would be a noteworthy event but not extraordinary. However, we are living in unprecedented and uncertain financial times and Pfizer’s possible purchase of Wyeth has serious implications for American taxpayers.
The Bush administration spent the last eight years trying to weaken and dismantle the US Food and Drug Administration (FDA). I thought the carnage at the agency would end in the waning days of one of America’s worst leaders. Sadly, I was mistaken.
News Day reported today that Wegmans Food Markets, a grocer with 72 locations in New York, Pennsylvania, New Jersey, Virginia and Maryland is giving away
Glassdoor.com a site that allows people to rate CEO and company performance selected
Targanta Therapeutics, a Cambridge, MA-based biopharmaceutical company, announced that it
It seems that every day a new American industry asks the US government for a bailout because of impending financial exigency. That said, I was somewhat surprised to learn today that the
We in America have grown accustomed to the constant barrage of
m another one of Grace Abrams’ grifting victims. Apparently, this individual purchased a sick puppy from Ms. Abrams several months ago which at one year old developed some problems that likely resulted from congenital defects due to inbreeding. This person told me that a friend of hers also purchased a ‘Havanese” from Ms. Abrams which they suspect really isn’t a Havanese (despite ‘papers’ that indicate that it is). As you may recall, we also received suspect pedigree papers for the dogs that we purchased from Ms. Abrams (
The
ou all know by now, American pharmaceutical companies have been intermittently laying off thousands of employees for the past two years or so. Many of the employees who have lost their jobs are R& D scientists, marketing personnel and sales representatives. This seemingly makes sense—because fewer drugs are being discovered and brought to market, fewer people are required to market and sell them. That said, isn’t discovering new drugs the currency and lifeblood of the pharmaceutical industry? How do these companies plan to stay in business if they continue to layoff employees who are seemingly responsible for developing new sources of revenue for them? Taking their cues from the IT and software industries, many US drug makers are beginning to either transfer R&D operations to foreign, company-owned research facilities or outsourcing some or all R&D activities to foreign contract research organizations (CROs).
ple have read the post and I am now starting to receive comments from people who have had similar experiences to mine after purchasing puppies from Ms. Roberts and her daughter Grace aka Dawn Abrams. Check out
I invite those of you who have been following this story to take a few minutes to read the comments that Donna Roberts continues to leave on my blog. Ms Roberts, who was convicted of several counts of animal cruelty in New Jersey last summer, is the mother of Grace aka “Dawn” Abrams who fraudulently sold me my dog Moose several months ago. Although, Ms. Roberts was not involved in the transaction between Grace and me, she continues to send me threatening and bullying e-mail messages proclaiming her daughter’s (and her own) innocence.
Beginning in 2009, Eli Lilly and Merck will post in online databases all payments made to doctors for speaking and consulting services. 
Previously, on the Bristol-Myers Squibb/ImClone Let’s Make a Deal Show.
A post at the Pharmalot blog
Like my kids frequently say when I mutter something obvious…”Like..DUH.! According to an
Just when you thought the obvious couldn’t be anymore obvious to US lawmakers, the Congressional Budget Office (CBO) today released a
Last year was a
No doubt that many of you already know that DTC advertising is an effective way for pharmaceutical companies to “push” their drugs. However, when I saw the amount of money that was spent on DTC in 2007 I was shocked! In 2007 alone, drug companies spent $5,375,117,382 on advertising. Yes, that's $5.375 billion dollars (think of how many research grants could have been funded or how much money could have been spent on universal healthcare!). The aggregate ROI for 25 pharma companies examined was impressive–totaling about $32 billion or roughly 7-fold!
As many of you may recall, Merck tried unsuccessfully last year to lobby state and federal officials to pass legislation that would require mandatory vaccination of girls aged 9-26 with
The newest culprit in the direct-to-consumer (DTC) television ad cat and mouse game between pharmaceutical manufacturers and US regulators is Cordis, a medical device subsidiary of Johnson & Johnson. The ad in question deals with promotion of the use of a
I learned late last evening that Ron Mardigian, founder and manager of Bio-Rad’s Biotechnology Explorer Program, died suddenly and unexpectedly in his sleep last December. Not surprisingly, I learned of his passing in a publication from Bio-Link, an NSF-funded organization committed to biotechnology training at the high school and community college levels.
I was reading the paper this morning and I happened upon an article about the uproar over Miley Cyrus aka Hannah Montana posing in a topless photo for Vanity Fair magazine (as it turns out she is not topless, but wrapped in a silk sheet in a very, alluring, adult-like pose). For those of you who care, the photo was taken by Annie Liebowitz, photographer extraordinaire. According to 15 year old Miley, it was a cool, artsy photo that she didn’t have a problem with– although she is now publicly stating that she is “embarrassed” by it! So, why are parents everywhere in America going ballistic over the photo?
The Boston Globe reported the other day
I just returned from my career development sojourn at this year’s FASEB meeting in San Diego, CA. Not surprisingly, all of my sessions were well attended. In fact, attendance at many of the presentations was standing room only. Again, this was not terribly surprising because the job market for graduate students and postdoctoral fellows for the last 5 years has been dismal. However, in contrast with past years, there was a noticeable and palpable difference in the attitudes of many of the students and postdocs who attended the sessions. In previous years, many career development participants seemed resigned to the possibility of a “jobless future”. However, this year there was a small but vocal group of participants who openly expressed their anger and resentment at the possibility of not finding a job after completing their training. I think that many graduate students and postdoctoral fellows have begun to realize that they are being exploited by a fundamentally flawed academic system and that they are “not going to take it anymore.”
Metals like copper and silver have long been known to possess antibacterial properties. I learned this as an undergraduate microbiology major circa 1972. That said, I didn’t know whether to laugh or cry when I read an article in today’s NY Times entitled
After an exhaustive nationwide search, FDA Commissioner Andrew von Eschenbach decided yesterday that Janet Woodcock, a career FDA staffer, was the best choice to lead the agency’s struggling Center for Drug Evaluation (CDER). For Dr. Woodcock who has been the acting head of CDER since September, this will be the second time that she was tapped to lead the center. She was previously appointed to the top CDER job in 1994 by then FDA Commissioner David Kessler (the last time FDA had any real leadership).
For the past year or more, the US media has been vociferously bashing tainted imported Chinese goods any time it can. The tainted products have ranged from toys to dog food and most recently to
I am old enough to remember when the 
.jpg)
The US Food and Drug Administration announced late last week
The New York Time reported today
As the cost of prescription drugs continues to spiral upward, the affordability and accessibility to prescription drugs and healthcare will likely be fiercely debated and may influence the outcome of the presidential election next November. Despite growing public concern over the cost of prescription drugs in the US,
for his intrepid reporting on the Vytorin scandal and keeping BioJobBlog abreast of all late-breaking news and rumors that are flying about.
Fred Hassan joined Schering Plough as its CEO five years ago. At that time, Mr. Hassan inherited a company that was being investigated by FDA for regulatory compliance violations and the SEC was investigating it former CEO for investing and accounting irregularities. Since his arrival at the company, Mr. Hassan increased sales of key products, filled an empty product pipeline and returned profitability to a company that posted losses in 2003 and 2004.
There are currently two injectable products on the market that are used to treat chronic Hepatitis C infections. Both products,
Health care spending in the United States grew
The New York times reported today
"Quite simply, life-saving drugs are irrelevant if they are not affordable"
There is a storm brewing around .jpg)
I was reading a post about the
Finally, three years after withdrawing its pain medication
There has recently been an inordinate amount of
Biotech giant Genentech is moving towards restricting the use of its cancer drug
The US Congress is poised this week to pass a new healthcare bill that gives the Food and Drug Administration (FDA) more authority to scrutinize drugs after they reach the market, including power to mandate label changes that warn of new risks. This is good news! 
In an attempt to dispel the notion that it is 
The Motley Fool published a
This morning,
The NY Times reported today that the New Jersey-based, health care giant, Johnson & Johnson has sued the American Red Cross for trademark infringement.
I read this fascinating
Maybe I can’t remember things as well as I used to, but I cannot recall a time when the safety of so many FDA-approved blockbuster pharmaceutical products has been questioned. The latest casualty is Avandia, GlaxoSmithKline’s blockbuster diabetes medication.
Sales are up, Eli Lilly’s share price closed at $59.28 yesterday and its blockbuster anti-psychotic drug Zyprexa® had worldwide sales in excess of $4.0 billion in 2006. So, what is wrong with this picture? Apparently, there are
Amgen announced yesterday that
Pfizer, the world’s largest pharmaceutical company, is on the ropes and in serious danger of imploding. After a decade long buying spree, gobbling up pharmaceutical companies that included Warner Lambert (Lipitor®) and Pharmacia (Celebrex®) and a host of smaller biotechnology companies including Agouron (antivirals) and Vicuron (antibiotics), the company has an extremely small drug pipeline. This is not surprising because Pfizer’s business model was to acquire rather than develop its own blockbuster drugs. As always, hindsight is 20/20 but it is patently obvious that Pfizer should have re-invested the billions the company made through sale of its blockbuster drugs (Celebrex®, Viagra®, Zoloft® and Lipitor®) into its own internal R & D programs to remain competitive in the long term.
The official debate over the future of follow-on biologics in the U.S. began in earnest today in Washington D.C. during hearings held by the House Oversight Committee. One of the first people to tesify before the Committee was Dr. Janet Woodcock, Deputy Director of FDA. She told committee members and representatives from the biotechnology and pharmaceutical industries that
I just finished teaching in the SUNY-Stonybrook Fundamentals of Biotechnology Certificate Program and the Georgetown Masters of Biotechnology Program for the year. Each year, I ask my students how much they think it costs to develop biotechnology drugs and they invariably give me the $800-$1.2 million figure that is bandied about by the Tufts Center for Drug Development. I contend that this number is grossly over-inflated when one realizes that the lion's share of development costs is used for advertising, promotion and sales. Because the pharmaceutical and biotechnology industries complain about the extremely high costs of drug development, they feel that it is their "god-given' right to charge exorbitant prices for their products.
The 